MARKET

CUE

CUE

Cue Biopharma Inc
NASDAQ
0.2394
-0.0115
-4.58%
After Hours: 0.2201 -0.0193 -8.06% 18:40 03/27 EDT
OPEN
0.2409
PREV CLOSE
0.2509
HIGH
0.2417
LOW
0.2224
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
1.050
52 WEEK LOW
0.2224
MARKET CAP
23.38M
P/E (TTM)
-0.8526
1D
5D
1M
3M
1Y
5Y
1D
Stocks to Watch: PMGC, Cue Biopharma
Dow Jones · 9h ago
Cue Biopharma Names Lucinda Warren Interim Chief Executive
TipRanks · 11h ago
Cue Biopharma CEO Azam Resigns, Financial and Business Chief Warren to Serve in Interim
Dow Jones · 11h ago
Cue Biopharma CEO Usman Azam steps down
TipRanks · 11h ago
CUE BIOPHARMA INC - LUCINDA WARREN TO CONTINUE AS CHIEF FINANCIAL AND BUSINESS OFFICER - SEC FILING
Reuters · 11h ago
Cue Biopharma President, CEO Usman Azam Steps Down, Effective March 26; Lucinda Warren Named Interim President, CEO
Benzinga · 12h ago
*Cue Biopharma Names Lucinda Warren as Interim President, CEO >CUE
Dow Jones · 12h ago
*Cue Biopharma: Usman Azam Resigns as President, CEO, From Board
Dow Jones · 12h ago
More
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Webull offers Cue Biopharma Inc stock information, including NASDAQ: CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.